口服西莫瑞韦用于治疗轻至中度新冠肺炎成年患者。 - Suppr | 超能文献

Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.

作者信息

Selvi-Sabater Pablo, de la Rubia Ortí Jose E, Urbieta-Sanz Elena

机构信息

Hospital Reina Sofia, Murcia, Spain

Universidad Católica de Valencia, Valencia, Spain.

出版信息

N Engl J Med. 2024 Apr 25;390(16):1534. doi: 10.1056/NEJMc2402378.

DOI:10.1056/NEJMc2402378

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.口服西莫瑞韦用于治疗轻至中度新冠肺炎成年患者。

N Engl J Med. 2024 Apr 25;390(16):1534. doi: 10.1056/NEJMc2402378.

2

Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.口服Simnotrelvir用于治疗轻至中度新冠肺炎成年患者。

N Engl J Med. 2024 Apr 25;390(16):1533-1534. doi: 10.1056/NEJMc2402378.

3

Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19. Reply.口服辛诺特韦治疗轻至中度新冠肺炎成年患者。回复。

N Engl J Med. 2024 Apr 25;390(16):1534-1535. doi: 10.1056/NEJMc2402378.

4

Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.口服索那瑞韦治疗成人轻度至中度 COVID-19 患者。

N Engl J Med. 2024 Jan 18;390(3):230-241. doi: 10.1056/NEJMoa2301425.

5

Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.新型口服小分子RdRp抑制剂SHEN26治疗新型冠状病毒肺炎的疗效和安全性：一项多中心、随机、双盲、安慰剂对照的II期临床试验

Virol J. 2025 Jan 25;22(1):16. doi: 10.1186/s12985-025-02631-y.

6

Simnotrelvir as a potential treatment for COVID-19.西美洛特韦作为一种治疗 COVID-19 的潜在药物。

Expert Opin Pharmacother. 2024 Feb;25(3):233-237. doi: 10.1080/14656566.2024.2323597. Epub 2024 Feb 27.

7

A randomized, double-blind, placebo-controlled trial of niclosamide nanohybrid for the treatment of patients with mild to moderate COVID-19.一项关于氯硝柳胺纳米复合物治疗轻至中度新型冠状病毒肺炎患者的随机、双盲、安慰剂对照试验。

Nat Commun. 2025 Aug 1;16(1):7084. doi: 10.1038/s41467-025-62423-4.

8

The efficacy and safety of inhaled peptide YKYY017 for COVID-19 patients with mild illness: a phase 2 randomized controlled trial.吸入式肽YKYY017用于轻症COVID-19患者的疗效与安全性：一项2期随机对照试验。

Nat Commun. 2025 Aug 7;16(1):7272. doi: 10.1038/s41467-025-62214-x.

9

Favorable Antiviral Effect of Metformin on SARS-CoV-2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of COVID-19.在一项 COVID-19 的随机、安慰剂对照临床试验中，二甲双胍对 SARS-CoV-2 病毒载量具有有利的抗病毒作用。

Clin Infect Dis. 2024 Aug 16;79(2):354-363. doi: 10.1093/cid/ciae159.

10

Real-world effectiveness of simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 during the omicron wave in China: a retrospective cohort study.在中国奥密克戎毒株流行期间，住院的新冠肺炎患者中，西米诺特韦-利托那韦与奈玛特韦-利托那韦的真实世界有效性：一项回顾性队列研究

BMC Infect Dis. 2025 Jul 1;25(1):840. doi: 10.1186/s12879-025-11195-9.

引用本文的文献

1

Real-world effectiveness of simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 during the omicron wave in China: a retrospective cohort study.在中国奥密克戎毒株流行期间，住院的新冠肺炎患者中，西米诺特韦-利托那韦与奈玛特韦-利托那韦的真实世界有效性：一项回顾性队列研究

BMC Infect Dis. 2025 Jul 1;25(1):840. doi: 10.1186/s12879-025-11195-9.

2

Genetic and Inflammatory Signatures Associated With Worse Prognosis in Hospitalized Patients With Severe SARS-CoV-2 Infection With and Without Diabetes.伴有和不伴有糖尿病的重症SARS-CoV-2感染住院患者中与预后较差相关的遗传和炎症特征。

J Med Virol. 2025 Jun;97(6):e70425. doi: 10.1002/jmv.70425.